BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $30,970,501 | -63.6% | 820,628 | -56.0% | 0.03% | -63.2% |
Q2 2023 | $85,036,373 | -34.2% | 1,866,470 | -41.4% | 0.09% | -37.4% |
Q1 2023 | $129,278,430 | +126.6% | 3,187,338 | +184.8% | 0.14% | +120.6% |
Q4 2022 | $57,051,944 | +316.5% | 1,119,324 | +340.1% | 0.06% | +293.8% |
Q3 2022 | $13,699,000 | -27.8% | 254,333 | -13.9% | 0.02% | -27.3% |
Q2 2022 | $18,973,000 | -68.8% | 295,398 | -62.3% | 0.02% | -61.4% |
Q1 2022 | $60,779,000 | -55.2% | 783,842 | -50.4% | 0.06% | -49.6% |
Q4 2021 | $135,698,000 | -28.9% | 1,580,828 | -33.3% | 0.11% | -34.3% |
Q3 2021 | $190,724,000 | +6.4% | 2,371,311 | +6.5% | 0.17% | +11.0% |
Q2 2021 | $179,220,000 | -29.5% | 2,226,331 | -26.1% | 0.16% | -36.7% |
Q1 2021 | $254,219,000 | -20.6% | 3,014,219 | -24.4% | 0.24% | -14.3% |
Q4 2020 | $320,016,000 | +45.7% | 3,988,232 | +46.1% | 0.29% | +27.1% |
Q3 2020 | $219,605,000 | +119.7% | 2,730,730 | +135.3% | 0.22% | +89.1% |
Q2 2020 | $99,936,000 | +548.7% | 1,160,706 | +511.7% | 0.12% | +395.8% |
Q1 2020 | $15,405,000 | +48.6% | 189,739 | +53.0% | 0.02% | +100.0% |
Q4 2019 | $10,368,000 | +703.1% | 123,987 | +739.9% | 0.01% | +500.0% |
Q3 2019 | $1,291,000 | -49.2% | 14,762 | -52.4% | 0.00% | -33.3% |
Q2 2019 | $2,542,000 | -84.8% | 31,037 | -84.9% | 0.00% | -86.4% |
Q1 2019 | $16,675,000 | -25.1% | 205,079 | -39.3% | 0.02% | -29.0% |
Q4 2018 | $22,249,000 | -37.6% | 338,029 | -26.9% | 0.03% | -27.9% |
Q3 2018 | $35,642,000 | -0.3% | 462,337 | -4.5% | 0.04% | -8.5% |
Q2 2018 | $35,762,000 | -48.9% | 484,319 | -55.0% | 0.05% | -50.5% |
Q1 2018 | $69,944,000 | +112.4% | 1,075,405 | +111.1% | 0.10% | +111.1% |
Q4 2017 | $32,930,000 | +78.5% | 509,439 | +73.3% | 0.04% | +60.7% |
Q3 2017 | $18,445,000 | -71.3% | 293,931 | -76.3% | 0.03% | -75.2% |
Q1 2017 | $64,213,000 | -4.7% | 1,238,205 | -18.6% | 0.11% | -1.7% |
Q4 2016 | $67,406,000 | +95.1% | 1,520,220 | +109.4% | 0.12% | +88.5% |
Q3 2016 | $34,552,000 | +25.3% | 725,889 | +19.0% | 0.06% | +19.6% |
Q2 2016 | $27,585,000 | +774.3% | 610,000 | +694.3% | 0.05% | +750.0% |
Q1 2016 | $3,155,000 | -32.0% | 76,799 | -36.8% | 0.01% | -25.0% |
Q4 2015 | $4,637,000 | -17.6% | 121,554 | -29.1% | 0.01% | 0.0% |
Q3 2015 | $5,629,000 | -80.5% | 171,354 | -58.6% | 0.01% | -81.8% |
Q2 2015 | $28,931,000 | -15.9% | 413,720 | -17.6% | 0.04% | -15.4% |
Q1 2015 | $34,401,000 | +3.7% | 502,213 | +11.0% | 0.05% | +23.8% |
Q4 2014 | $33,159,000 | -48.8% | 452,440 | -49.9% | 0.04% | -50.0% |
Q3 2014 | $64,799,000 | -35.9% | 902,868 | -35.4% | 0.08% | -39.1% |
Q2 2014 | $101,067,000 | +57.1% | 1,397,881 | +59.9% | 0.14% | +50.0% |
Q1 2014 | $64,328,000 | -16.2% | 874,267 | -20.8% | 0.09% | -12.4% |
Q4 2013 | $76,728,000 | +261.8% | 1,103,200 | +241.7% | 0.10% | +218.2% |
Q3 2013 | $21,208,000 | -68.6% | 322,856 | -66.9% | 0.03% | -74.0% |
Q2 2013 | $67,627,000 | – | 976,292 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |